Jun 22, 2020
Sutro Biopharma Presents New Preclinical Data at 2020 AACR Virtual Annual Meeting II Suggesting Synergy between its STRO-002 Antibody-Drug Conjugate and Immune Checkpoint Inhibitors Resulting in Tumor Regression and Adaptive Anti-Tumor Immunity
Jun 09, 2020
Sutro Biopharma to Present New Preclinical Data on its STRO-002 Antibody-Drug Conjugate at the Upcoming AACR 2020 Virtual Meeting on June 22, 2020
May 29, 2020
Rakuten Medical Establishes Illuminox(TM) Alliance Institutes to Accelerate Development of Cancer Therapies, Announcing The National Cancer Center Japan as the First Institute to Join the Alliance
Apr 30, 2020
Trio Pharmaceuticals, Inc. and Ajinomoto Bio-Pharma Services Enter into a Development Collaboration for a Novel Antibody Therapeutic
Apr 02, 2020
Bolt Biotherapeutics Appoints Nathan Ihle, Ph.D., as Vice President of CMC and Quality
Mar 31, 2020
Global Antibody Drug Conjugates Drug Sales, Pipeline Analysis (By Phase, Linker, Technology, and Indication) & Global Market Forecasts to 2023
Feb 18, 2020
Antibody Drug Conjugates (ADCs)-Linker and Conjugation Technologies Market, 2019-2030
Feb 04, 2020
Navrogen and Levena Announce Collaboration to Develop Antibody Drug Conjugates (ADCs) to Treat Humoral Immuno-Suppressed Cancers
Jan 21, 2020
OBI Pharma Granted U.S. FDA Orphan Drug Designation for the Treatment of Gastric Cancer for Its Antibody-Drug Conjugate (ADC) Targeted Cancer Therapy, OBI-999
Dec 26, 2019
OBI Pharma Granted FDA Orphan Drug Designation for the Treatment of Pancreatic Cancer for Its Antibody-Drug Conjugate (ADC) Targeted Cancer Therapy, OBI-999
Dec 18, 2019
OBI Pharma Announces Initiation of a Phase 1/2 Study of Its Antibody-Drug Conjugate (ADC) Targeted Cancer Therapy, OBI-999
Nov 04, 2019
Daiichi Sankyo Files Declaratory Judgement Action Related to its Proprietary Antibody Drug Conjugate Technology
Sep 16, 2019
Seattle Genetics and Astellas Announce U.S. FDA Grants Priority Review for Enfortumab Vedotin Biologics License Application in Locally Advanced or Metastatic Urothelial Cancer
Sep 03, 2019
OBI Pharma Announces U.S. FDA Clearance of IND Application for a Phase 1/2 Study of its Antibody-Drug Conjugate (ADC) targeted cancer therapy, OBI-999
Aug 29, 2019
ADCendo Accepted into the Creation House Program of BioInnovation Institute (BII), Securing a Convertible Loan of 10 Million DKK
Aug 01, 2019
Monoclonal Antibody Therapeutics Market is Expected to Rise at 12.6% CAGR; Surging Cancer Cases Underpin Demand in Market - TMR
Jun 28, 2019
BioAtla Appoints Eric Sievers, M.D., As Chief Medical Officer
Jun 04, 2019
RemeGen, Ltd. Announces Positive Results from RC48 Clinical Trial in HER2-Positive Metastatic or Unresectable Urothelial Cancer
Jun 03, 2019
Astellas and Seattle Genetics Announce Antibody-Drug Conjugate Enfortumab Vedotin Produced Tumor Response Rate of 44 Percent in Patients with Most Common Type of Advanced Urothelial (Bladder) Cancer
May 16, 2019
Sutro Biopharma Announces Presentation at the 2019 European Hematology Association Congress